Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse EventsZhaoliang Huang, Baiyong Li, Na Chen et al.|Frontiers in Immunology|2022Cited by 42
521 AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studiesTingting Zhong, Min Jing, Zhaoliang Huang et al.|Regular and Young Investigator Award Abstracts|2022Cited by 18